U.S. Point-of-Care Molecular Diagnostics Market Projected To Raise At USD 3.92 Billion By 2030

 San Francisco, 24 December 2024: The Report U.S. Point-of-Care Molecular Diagnostics Market Size, Share & Trends Analysis Report Test Location, By Application (Infectious Diseases, Oncology, Prenatal Testing), By Technology (PCR, Sequencing), By End-use, And Segment Forecasts, 2024 - 2030

The U.S. point-of-care molecular diagnostics market size to reach USD 3.92 billion in 2030 and is projected to grow at a compound annual growth rate (CAGR) of 1.7% from 2024 to 2030. The growth of the market is driven by rise in end-user awareness, along with the increased efficiency of the testing methods and favorability for non-laboratory testing. For instance, in the U.S., approximately 1% infants are diagnosed with congenital heart diseases (CHDs) every year. However, advancements in prenatal testing have led to rapid detection of genetic biomarkers in embryos, thus leading to early diagnosis of CHDs and other genetic disorders.

The U.S. point-of-care molecular diagnostics market growth is positively impacted by the county’s patient-centric healthcare services. Thus, the demand for POC diagnostics has led to significant market growth. According to a study in the BioChip Journal in 2021, pathogen-specific treatment provided by multiplex POC tests is crucial in remote critical care, thus witnessing increased adoption in laboratory facilities. The applications of POC molecular testing range from glucose tests to complex coagulation testing. Due to the easy accessibility and reduced timeframe of diagnosis, many clinics are opting for POC testing, as opposed to conventional testing methods.

The increasing incidence of genetic disorders as well as infectious diseases, such as sexually transmitted diseases (STIs, namely HIV, HPV) and dengue, have led to fastened technological developments in molecular diagnostics. Moreover, the introduction of healthcare information systems, paired with the advent of teleconsultation services, has led to increased awareness and adoption of POC testing. 

Access Research Report of U.S. Point-of-Care Molecular Diagnostics Market @ https://www.grandviewresearch.com/industry-analysis/us-point-of-care-molecular-diagnostics-market-report

Recent Developments

• In February 2024, BD, a U.S. based medical technology company, announced that they have begun clinical trials for a rapid Point-of Care Molecular Dx instrument and an assay to detect STIs.
• In November 2023, binx health, a healthcare technology and diagnostics company, announced its agreement with Fisher Healthcare, a part of Thermo Fisher Scientific, to expand the nationwide distribution of their molecular POC platform, bimx io, in the U.S.
• In March 2023, Lucira Health, a U.S.-based company that was acquired by Pfizer in April 2023, announced the launch of the first and only at-home COVID-19 and flu tests in the U.S., a test approved by the FDA under Emergency Use Authorization (EUA) for OTC usage at home and other nonlaboratory locations.

Key U.S. Point-of-Care Molecular Diagnostics Company Insights

Some of the key players operating in the U.S. point-of-care molecular diagnostics market include Abbott Laboratories; QIAGEN; F. Hoffman-La Roche Ltd; bioMerieux; and BD. Numerous key players are undertaking strategic initiatives such as expansion, product introductions, mergers, and acquisitions, while also focusing on increasing product reach in the U.S. Several market participants are investing in research and development initiatives, making the market susceptible to further growth.

Key U.S. Point-of-Care Molecular Diagnostics Companies:

• QIAGEN
• Danaher
• Thermo Fisher Scientific, Inc.
• BD
• F. Hoffman-La Roche AG
• Charles River Laboratories
• Quest Diagnostics Incorporated
• Bio-Rad Laboratories, Inc.
• Hologic Inc.
• Agilent Technologies, Inc.

About Grand View Research

Grand View Research is an India & U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services.

For More Information: https://www.grandviewresearch.com/horizon